Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for reducing brain injury after aneurysmal subarachnoid hemorrhage
NL-OMON22901Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Single-arm trial of eculizumab in subarachnoid hemorrhage (SAH), sponsored by University Medical Center Utrecht. Primary endpoint: C5a concentration in cerebrospinal fluid. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
eculizumab
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NL-OMON22901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22901.